There is news of expanding coverage of oral RRMS (Relapsing-remitting multiple sclerosis) drugs.

According to industry sources on the 8th, after Mavenclad (Cladribine, Merck) was listed in insurance benefits in the second half of last year, Sanofi Genzyme's primary drug Aubagio was expanded from February.

In the case of Aubagio, additional benefits are applied to patients with Relapsing-Remitting Multiple Sclerosis (RRMS) who meet McDonald's diagnostic criteria through examination by a neurologist and who can go to the outpatient clinic.

The key to the expansion of this benefit standard is to be able to follow the judgment of experts based on the McDonald standard diagnosis